ATORM-C
Phase 1Intestinal organoid therapy derived from the patient's own adult stem cells; received MFDS approval in March 2026 for a Phase 1 trial in Crohn's disease with colonic ulcers.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Received approval for a Phase 1 trial of its intestinal organoid therapy in Crohn's disease and runs a GMP center in Gwangmyeong.
Roles often seen at this stageClinical & PV · Research & development · Manufacturing & MSAT
Develops regenerative therapies and drug-efficacy testing solutions based on organoids grown from stem cells in 3D culture; listed on KOSDAQ in May 2025.
Intestinal organoid therapy derived from the patient's own adult stem cells; received MFDS approval in March 2026 for a Phase 1 trial in Crohn's disease with colonic ulcers.
Organoid-based efficacy testing solution for new materials, first commercialized in Korea in 2020.
GMP center of about 250 pyeong at SK Techno Park in Gwangmyeong, licensed for manufacturing and cell processing in Q4 2022.
Received approval for a Phase 1 trial of ATORM-C in Crohn's disease, enrolling 9 to 18 patients at Asan Medical Center in Seoul.
Listed on KOSDAQ through the technology special listing route, raising about 25.2 billion won.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.